Seagen Inc. (SGEN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Bothell, WA, アメリカ. 現CEOは David R. Epstein.
SGEN を有する IPO日 2001-03-09, 3,256 名の正社員, に上場 NASDAQ Global Select, 時価総額 $43.15B.
Seagen Inc. is a biotechnology company headquartered in Bothell, Washington, specializing in the development and commercialization of cancer therapies. The company's commercial portfolio includes ADCETRIS for Hodgkin lymphoma and CD30-positive T-cell lymphomas, PADCEV for advanced urothelial cancer, and TUKYSA for HER2-positive breast cancer, alongside several pipeline candidates such as TIVDAK for cervical cancer and multiple novel antibody-drug conjugates targeting various oncology indications. Seagen operates globally and maintains strategic collaboration agreements with leading pharmaceutical companies including Takeda, Merck, and Genmab. The company was founded in 1997 as Seattle Genetics and rebranded as Seagen Inc. in 2020.
